Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurinia PharmaceuticalsFRA:IKAP +0.77%81 Equity-to-Asset is 0.78 as of Jun. 2026, which is 5% below its 10-year median of 0.82. GuruFocus rates FRA:IKAP with a GF Score™ of 81/100 and a GF Value™ of €12.72 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,413 Biotechnology companies, Aurinia Pharmaceuticals ranks better than 62.49% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Aurinia Pharmaceuticals Equity-to-Asset Related Terms
Aurinia Pharmaceuticals Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IKAP vs PVLA, SRPT, URGN: Equity-to-Asset Comparison
For the Biotechnology subindustry, Aurinia Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurinia Pharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aurinia Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals (FRA:IKAP) has a Equity-to-Asset of 0.78 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aurinia Pharmaceuticals and its competitors. This is near median its historical median of 0.82. Over the past decade, Aurinia Pharmaceuticals' Equity-to-Asset has ranged from 0.61 to 0.92. According to the industry distribution chart, Aurinia Pharmaceuticals ranks #530 out of 1413 companies in the Biotechnology industry, placing it in the top 37.5%.
Is Aurinia Pharmaceuticals' Equity-to-Asset too high?
Aurinia Pharmaceuticals' current Equity-to-Asset of 0.78 is near median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 0.92. The Biotechnology industry median Equity-to-Asset is 0.69. Aurinia Pharmaceuticals' value of 0.78 is 13% above this industry median. Based on the distribution chart, Aurinia Pharmaceuticals ranks #530 out of 1413 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aurinia Pharmaceuticals has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Equity-to-Asset compare to PVLA and SRPT?
According to the Biotechnology industry distribution chart, Aurinia Pharmaceuticals ranks #530 out of 1413 companies for Equity-to-Asset. This puts Aurinia Pharmaceuticals in the upper half of its industry. The industry median Equity-to-Asset is 0.69. Aurinia Pharmaceuticals' value of 0.78 is 13% above this benchmark. Historically, Aurinia Pharmaceuticals' own Equity-to-Asset has ranged from 0.61 to 0.92 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 0.69, Aurinia Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurinia Pharmaceuticals's current Equity-to-Asset of 0.78 is 13% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aurinia Pharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurinia Pharmaceuticals's current Equity-to-Asset is 0.78, which is near median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (FRA:IKAP) is currently considered Fairly Valued. The stock's GF Value™ is €12.72, compared to a current price of €13.82 — trading 8.6% above its estimated fair value. The current Equity-to-Asset is 0.78, which is near median its 10-year median of 0.82 and 13% above the Biotechnology industry median of 0.69. Aurinia Pharmaceuticals' overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Aurinia Pharmaceuticals (FRA:IKAP), the current Equity-to-Asset is 0.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurinia Pharmaceuticals (FRA:IKAP) Overvalued in 2026?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued.
The current stock price of €13.82 is trading 8.6% above its estimated GF Value™ of €12.72.
GuruFocus considers Aurinia Pharmaceuticals to be Fairly Valued.
Key valuation signals for FRA:IKAP:
Equity-to-Asset: 0.78 (near median its 10-year median of 0.82)
GF Value™: €12.72 vs. price of €13.82 (8.6% above fair value)
Industry Position: 13% above the Biotechnology median (#530 of 1413)
No single metric tells the full story. See the FRA:IKAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
81GF Score
Get the complete analysis for FRA:IKAP
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IKAP has been successfully added to your 
